AI modeling transforms drug development from a numbers game of screening millions of compounds to an engineering discipline. Researchers can model molecular systems upfront, understand key parameters, and design solutions for a specific problem, turning a costly screening process into a rapid, targeted design cycle.

The traditional scientific method in materials science—hypothesize, experiment, learn—is being replaced. AI enables a new paradigm: treating the vast space of all possible molecules as a searchable database. Scientists can now query for materials with desired properties, radically accelerating discovery.

NewLimit combines artificial intelligence with high-throughput biology in a virtuous cycle. Their AI model, Ambrosia, predicts which gene combinations will be effective. These predictions are then tested in thousands of parallel experiments, which in turn generate massive datasets to further train and refine the AI, accelerating discovery.

A major failure point for natural products is late-stage toxicity. Novogaia mitigates this by simultaneously screening for bioactivity and analyzing chemical properties with mass spectrometry. This prioritizes active compounds that also have favorable drug-like characteristics from the very beginning, reducing downstream risk.

The future of AI in drug discovery is shifting from merely speeding up existing processes to inventing novel therapeutics from scratch. The paradigm will move toward AI-designed drugs validated with minimal wet lab reliance, changing the key question from "How fast can AI help?" to "What can AI create?"

Early AI models advanced by scraping web text and code. The next revolution, especially in "AI for science," requires overcoming a major hurdle: consolidating and formatting the world's vast but fragmented scientific data across disciplines like chemistry and materials science for model training.

Novonesis has shifted enzyme discovery from the lab to computers. Using AI tools like AlphaFold, they predict protein structures and identify new enzyme families based on structural motifs rather than sequence similarity. This allows them to find novel functionalities much faster than traditional methods.

The ultimate goal isn't just modeling specific systems (like protein folding), but automating the entire scientific method. This involves AI generating hypotheses, choosing experiments, analyzing results, and updating a 'world model' of a domain, creating a continuous loop of discovery.

Instead of screening billions of nature's existing proteins (a search problem), AI-powered de novo design creates entirely new proteins for specific functions from scratch. This moves the paradigm from hoping to find a match to intentionally engineering the desired molecule.